Search

Your search keyword '"[Lu-177-DOTA(0)"' showing total 2 results
Start Over Descriptor "[Lu-177-DOTA(0)"
2 results on '"[Lu-177-DOTA(0)"'

1. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

Author

Bert A. Bonsing, Elisabeth J. M. Nieveen van Dijkum, Eric P. Krenning, Wouter W. de Herder, Ronald R. de Krijger, Casper H.J. van Eijck, Esther I. van Vliet, Richard A Feelders, Tessa Brabander, Jaap J.M. Teunissen, Dik J. Kwekkeboom, Boen J Kam, Radiology & Nuclear Medicine, Surgery, Pathology, Internal Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, and Other Research

Subjects
Adult, Male, neoadjuvant treatment, Oncology, medicine.medical_specialty, medicine.medical_treatment, Splenectomy, Kaplan-Meier Estimate, Neuroendocrine tumors, Octreotide, pancreatic neuroendocrine tumor, Gastroenterology, Disease-Free Survival, Pancreaticoduodenectomy, surgery, Whipple Procedure, Young Adult, chemistry.chemical_compound, Pancreatectomy, Pancreatic tumor, Internal medicine, [Lu-177-DOTA(0), medicine, Humans, Radiology, Nuclear Medicine and imaging, Tyr(3)]octreotate, Neoplasm Metastasis, Neoadjuvant therapy, Aged, Aged, 80 and over, Octreotate, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Survival Analysis, Neoadjuvant Therapy, [Lu-177-DOTA(0),Tyr(3)]octreotate, Pancreatic Neoplasms, chemistry, Female, PRRT, Neoplasm Grading, Radiopharmaceuticals, business
Abstract

Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for which surgery has almost the only potential for cure. When surgery is not possible because of tumor size and vascular involvement, neoadjuvant treatment with [Lu-177-DOTA(0),Tyr(3)]octreotate (Lu-177-octreotate) may be an option. Methods: We studied 29 Dutch patients with a pathology-proven nonfunctioning pancreatic NET treated with Lu-177-octreotate. All patients had a borderline or unresectable pancreatic tumor (group 1) or oligometastatic disease (defined as liver metastases) (group 2). Progression-free survival (PFS) was analyzed using the Kaplan Meier method and Cox proportional hazards modeling. Results: After the treatment with Lu-177-octreotate, successful surgery was performed in 9 of 29 patients (31%). Six patients had a Whipple procedure, 2 patients had a pylorus-preserving pancreaticoduodenectomy, and 1 patient had a distal pancreatectomy and splenectomy. The median PFS was 69 mo for patients with successful surgery and 49 mo for the other patients. For comparison, the median PFS in 90 other patients with a nonfunctioning pancreatic NET with more than 3 liver metastases or other metastases was 25 mo. Conclusion: Neoadjuvant treatment with Lu-177-octreotate is a valuable option for patients with initially unresectable pancreatic NETs.

Published
2015
Full Text
View/download PDF

2. Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Author

Sandström, Mattias, Garske, Ulrike, Granberg, Dan, Sundin, Anders, Lundqvist, Hans, Sandström, Mattias, Garske, Ulrike, Granberg, Dan, Sundin, Anders, and Lundqvist, Hans

Abstract

In recent years, targeted radionuclide therapy with [Lu-177-DOTA(0), Tyr(3)]octreotate for neuroendocrine tumours has yielded promising results. This therapy may be further improved by using individualized dosimetry allowing optimization of the absorbed dose to the tumours and the normal organs. The aim of this study was to investigate the feasibility and reliability of individualized dosimetry based on SPECT in comparison to conventional planar imaging. Attenuation-corrected SPECT data were analysed both by using organ-based volumes of interest (VOIs) to obtain the total radioactivity in the organ, and by using small VOIs to measure the tissue radioactivity concentration. During the first treatment session in 24 patients, imaging was performed 1, 24, 96 and 168 h after [Lu-177-DOTA(0), Tyr(3)]octreotate infusion. Absorbed doses in non tumour-affected kidney, liver and spleen were calculated and compared for all three methods (planar imaging, SPECT organ VOIs, SPECT small VOIs). Planar and SPECT dosimetry were comparable in areas free of tumours, but due to overlap the planar dosimetry highly overestimated the absorbed dose in organs with tumours. Furthermore, SPECT dosimetry based on small VOIs proved to be more reliable than whole-organ dosimetry. We conclude that SPECT dosimetry based on small VOIs is feasible and more accurate than conventional planar dosimetry, and thus may contribute towards optimising targeted radionuclide therapy.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results